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Plasma homocysteine levels are related to medium-term venous graft 
degeneration in coronary artery bypass graft patients
Introduction
Arterial and venous conduits have been used for coronary 
artery bypass grafting (CABG) to alleviate serious myocardial 
ischemia. Saphenous venous grafts (SVGs) have been verified 
to carry a higher risk of developing accelerated graft disease in-
duced by hereditary, environmental, or systemic or local factors 
in complex interactions (1, 2). It is known that shear stress and 
local blood flow affect graft patency (3). Despite the improve-
ment of surgical techniques and experiences, CABG still poses a 
challenge in secondary cardiovascular prevention. Holistic risk 
stratification is often unworkable or incompletely established, or 
managing comorbidities proves ineffective (2).
The aim of our investigation was to map the risk factors of 
chronic SVG disease in relation to the individual—on both per 
patient and per graft basis. Our investigation focused on homo-
cysteine (Hcy), a sulfur-containing amino acid formed during the 
metabolism of methionine. Its association with atherosclerotic 
lesions of native vessels was published by McCully in the early 
1960s (4). In the last half century, several clinical and experimental 
studies have clarified that elevated blood Hcy levels are related 
to atherosclerotic disease (5, 6). However, trials investigating the 
effect of the lowering of Hcy levels yielded controversial results 
concerning risk reduction in cardiovascular patients (7, 8). Fur-
thermore, only very limited data are available regarding the effect 
of Hcy on medium- and long-term venous graft patency (9, 10).
Objective: Saphenous venous grafts (SVGs) are established choices for coronary artery bypass grafting (CABG); however, their lumen patency 
is limited. Our goal was to investigate the risk factors of SVG degeneration.
Methods: Seventy-five patients (mean age, 57.5±10.4 years) with 133 SVG conduits who had cardiac catheterization ≥1 year after CABG were 
selected; follow-up period was 67.6±36.8 months. Patients were divided into 3 groups according to angiographic status at follow up [intact: <20% 
(n=23); narrowed: 20–99% (n=24); and occluded (n=28)]. Baseline clinical conditions were evaluated in relation to follow-up angiography. As 
onset date of chronic total occlusions is usually uncertain, they arise typically from thrombotic lesions; thus, their value in evaluation is limited.
Results: There were no significant differences between the 3 groups in clinical parameters. Linear correlation analysis found significant (p<0.01) 
positive connection of SVG disease (luminal diameter reduction 20–99%) with C-reactive protein (CRP) and homocysteine (Hcy), as well as 
between CRP and Hcy. Multiple regression analysis showed plasma Hcy level to be significantly related to graft diameter reduction normalized 
to time elapsed until angiography in narrowed grafts: 1 μmol/L increase of Hcy was associated with 0.053%/month decrease in lumen diameter 
(p<0.01; R2=0.428); extrapolating: +10 μmol/L higher Hcy level during 5 years is associated with 32.1% lumen reduction.
Conclusion: Medium- to long-term SVG degeneration is related to elevated plasma total Hcy in patients with sub-occlusive graft stenosis, while 
in cases with intact SVGs, the beneficial local flow conditions may protect the grafts from degeneration. (Anatol J Cardiol 2016; 16: 000-00)
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Methods
The present study was based on retrospective data col-
lected from our clinical database between 2001 and 2013. The 
scientific plan had previously been submitted to and approved 
by the Institutional Ethics Committee. All details potentially re-
vealing the identity of the subjects were handled according to 
the ICH GCP guidelines and authority regulations. Data were 
collected from 75 SVG recipients (aged ≥30 years) who had ≥1 
cardiac catheterization because of symptoms of coronary artery 
disease (CAD) at least 1 year after CABG. Patients <1 year af-
ter CABG were excluded to avoid considering technical failure 
Table 1. Perioperative clinical characteristics of patients in subgroups per follow-up status (n=75)
   Per patient*
Variable Intacta Narrowedb Occludedc P
Total no. of patients n=75; 23 24 28 –
Age, years, (mean±SD) 59.4±10.2 53.5±8.8 59.1±10.1 NS
Male, n, (%) 13 (56.5) 22 (91.7) 19 (67.8) NS
Diabetes†, n, (%) 9 (39.1) 3 (12.5) 14 (50.0) NS
Hypertension††, n, (%) 16 (69.5) 16 (66.7) 21 (75.0) NS
Hyperlipidemia‡, n, (%) 17 (73.9) 19 (79.2) 26 (92.8) NS
Myocardial infarction, n, (%) 14 (60.8) 15 (62.5) 20 (71.4) NS
Stroke, n, (%) 2 (8.7) 2 (8.3) 3 (10.7) NS
Peripheral vascular disease, n, (%) 7 (30.4) 3 (12.5) 9 (32.1) NS
Smoking#, n, (%) 3 (13.0) 5 (20.8) 7 (25.0) NS
EF, (%, mean±SD) 52.6±9.5 48.6±10.0 48.0±10.7 NS
Systolic blood pressure, mm Hg, (mean±SD) 136.1±16.8 136.7±14.9 133.8±13.0 NS
Diastolic blood pressure, mm Hg, (mean±SD) 80.9±12.5 83.1±10.8 79.6±5.9 NS
Creatinine, μmol/L, mean±SD) 85.7±15.3 88.4±20.4 87.7±17.3 NS
HDL, mmol/L, (mean±SD) 1.1±0.2 1.0±0.2 1.1±0.3 NS
LDL, mmol/L, (mean±SD) 3.1±0.6 3.4±0.9 3.3±0.6 NS
Total-cholesterol, mmol/L, (mean±SD) 5.1±0.7 5.3±1.0 5.4±0.8 NS
TG, mmol/L, (mean±SD) 1.9±0.7 2.0±1.6 2.2±1.4 NS
Lipoprotein(a), nmol/L, (mean±SD) 421.4±590.4 494.6±514.7 521.9±593.1 NS
CRP, mg/L, (mean±SD) 5.1±4.7 5.5±5.0 4.5±3.6 NS
Homocysteine, μmol/L, (mean±SD) 15.9±7.6 16.0±15.2 15.1±4.7 NS
Folate, nmol/L, (mean±SD) 13.9±7.6 11.0±4.3 12.2±3.6 NS
Vitamin B12, pmol/L, (mean±SD) 232.6±129.0 251.1±111.2 248.2±103.4 NS
Follow up time, month, (mean±SD) 70.1±33.5 74,6±39.1 64.1±38.9 NS
Affected grafts, n, (%) – – – NS
to LAD 7 (30.4) 7 (29.2) 8 (28.6) NS
to CX 9 (39.2) 16 (66.6) 14 (50.0) NS
to RCA 7 (30.4) 1 (4.2) 6 (21.4) NS
Indication of post CABG coronary angiography – – – NS
Stable angina, n, (%) 15 (65.2) 15 (62.5) 20 (71.5) NS
Unstable angina, n, (%) 4 (17.4) 8 (33.3) 5 (17.8) NS
Acute coronary syndrome, n, (%) 1 (4.3) 1 (4.2) 0 (0.0) NS
Others, n, (%) 3 (13.0) 0 (0.0) 3 (10.7) NS
*Ranking: patients with >1 SVG were classified according to their most severe graft’s status. Definitions: Intact: <20% SVG lumen diameter reduction; Narrowed: Between 20% and 
99% SVG lumen diameter reduction; and Occluded: SVG with closed lumen. CABG - coronary artery bypass grafting; Chol - cholesterol; CRP-C - reactive protein; CX - circumflex coro-
nary artery; EF - ejection fraction; Hcy - homocysteine; HDL - high-density lipoprotein; LAD - left anterior descending coronary artery; LDL - low-density lipoprotein; NS - not significant; 
RCA - right coronary artery; SVG - saphenous venous graft; TG - triglyceride
and premature thrombosis as a different manifestation of SVG 
disease. Patients with renal dysfunction (serum creatinine >160 
μmol/L), known history of diabetic ketoacidosis, left ventricular 
ejection fraction ≤35%, or intervened SVGs were also excluded.
The following peri-CABG clinical parameters were collected: 
demographic characteristics; medical history (e.g., onset of CAD, 
previous MI, stroke) and history of cardiovascular risk factors 
(e.g., hypertension, diabetes, hyperlipidemia); smoking history 
and smoking status; CAD-related drug therapy; systolic and dia-
stolic blood pressure; left ventricular ejection fraction (EF); and 
levels of plasma Hcy, LDL-cholesterol, HDL-cholesterol, total 
cholesterol, triglycerides, apo-AI, apo-B, creatinine, high-sensi-
tivity C-reactive protein, folate, and vitamin B12. Blood param-
eters were determined by standard laboratory techniques us-
ing validated methods. As regards CABG, the number of venous 
conduits, location, host coronary parameters, previous coronary 
interventions, and data of repeat cardiac catheterization were 
documented.
Coronary angiographies were performed using the standard 
technique according to the accepted guidelines with Philips 
Integris X-ray equipment (Inturis Suite ViewerLite v1.0; Philips, 
The Netherlands). Baseline SVG status at CABG was deemed 
as intact. Follow-up coronary angiograms were indicated in the 
case of clinical symptoms. The diagnosis of SVG disease was 
based on independent judgement of repeat coronary angiogra-
phies by 2 expert cardiologists; SVGs were classified accord-
ing to their lumen status (diameter stenosis; %) at repeat coro-
nary angiography. By excluding coronary angiographies within 
12 months after CABG, it was possible to clearly distinguish 
technical failure or premature thrombosis caused short-term 
SVG degenerations. Our approach ensured time proportional 
evaluation of grafts by normalizing the change of diameter ac-
cording to the time elapsed during follow-up. In this way, the 
selection bias could not affect the observed relations and re-
flected the “real-life” complexity of graft degeneration where 
the same pathophysiological conditions may result in different 
manifestations of SVG disease in different grafts of the same 
patient. Grafts were graded as intact with a <20% lumen diam-
eter reduction similar to large vascular trials (11, 12); narrowed, 
between 20% and 99%; or occluded (closed lumen). Based on 
previous observations that chronic occlusions often arise from 
thrombotic lesions (13, 14) with undefined onset date, occluded 
SVGs were not used for comparison.
SVG conduits were evaluated both per patient and per graft 
level. Patients having >1 SVG with different luminal diameter 
status at follow-up were graded according to the more severe 
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Table 2. Relationship of known or potential risk factors of SVG disease in “intact” and “narrowed” SVG patient group (n=47)
  SVG narrowing 
  (%)/month Age Creatinine HDL LDL TG CRP Hcy Folic acid Vit B12 EF
SVG narrowing 
(%)/month
Age 0.148 
  0.320
Creatinine 0.231 -0.017 
  0.118 0.907
HDL 0.252 -0.082 -0.009 
  0.091 0.586 0.951
LDL -0.028 -0.053 0.098 -0.157 
  0.850 0.721 0.514 0.297
TG -0.002 -0.132 0.091 -0.336* -0.092 
  0.989 0.377 0.543 0.022 0.538
CRP 0.483** 0.122 0.159 0.002 0.214 0.036 
  0.0001 0.437 0.310 0.988 0.168 0.816
Hcy 0.752** 0.248 0.268 0.248 -0.092 0.015 0.509** 
  0.0001 0.093 0.068 0.096 0.539 0.923 0.0001
Folic acid -0.052 -0.117 0.166 0.188 -0.187 -0.205 -0.109 -0.012 
  0.730 0.438 0.270 0.216 0.213 0.171 0.492 0.935
Vit B12 -0.254 -0.235 -0.074 0.083 -0.191 -0.128 -0.167 -0.253 0.443** 
  0.730 0.117 0.627 0.586 0.204 0.398 0.289 0.090 0.0002
EF -0.055 0.134 -0.279 0.073 -0.163 -0.056 -0.048 0.020 -0.075 -0.70 
  0.713 0.371 0.057 0.628 0.273 0.709 0.762 0.895 0.621 0.645
Method of analysis: Pearson correlation analysis. The r-value is shown above; P-value is shown below in the cells. Significance is marked by bold letter and asterisk (*): *P<0.05; 
**P<0.01. SVGs were classified as according to their luminal diameter status at repeat coronary angiography as intact with ≤20% and narrowed with a luminal diameter narrowing be-
tween >20% and 99%. CRP-C - reactive protein; EF - ejection fraction; Hcy - homocysteine; HDL - high-density lipoprotein; LDL - low-density lipoprotein; SVG - saphenous venous graft; 
TG - triglyceride; vit B12 - vitamin B12
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graft’s status classifying them into 1 of the 3 above-mentioned 
patient groups, and absolute values of luminal diameter reduc-
tion were averaged. Conduits with any kind of intervention were 
excluded. We complemented evaluation at per graft level as 
well. This way, by having an increased item of data about SVGs, 
stronger confidence of the statistical analysis was achieved. 
Categorical variables are reported as percentages, while 
continuous variables are reported as mean±standard deviation 
(SD). The Kolmogorov–Smirnov test was used to test the nor-
mality of parameters. The equality of data of patient groups was 
tested by analysis of variance (ANOVA). The effect of elevated 
Hcy on the risk of SVG degeneration was analyzed by stepwise 
forward linear regression analysis, with a p value significance 
level of <0.05. Analyses were performed using the Statistical 
Package for the Social Sciences (IBM SPSS Statistics software 
v20.0.0), USA. 
Results
Mean follow up time was ≥5 years (67.6±36.8 months). The 
elapsed time until follow-up coronary angiography did not differ 
between the 3 groups. Clinical characteristics and laboratory 
findings regarding different patient groups are listed in Table 
1. Mean patient age was 57.5±10.4 years, reason of post-CABG 
repeat coronary angiography was primarily stable angina, and 
more than two-thirds of patients showed vascular signs of SVG 
disease (stenosis/occlusion). Demographics, medical history, 
indication of repeat coronary angiography, clinical parameters, 
and risk factors did not differ significantly between the groups 
according to ANOVA.
The potential connection among clinical and angiography 
parameters were evaluated in intact and narrowed groups by 
univariate correlation analysis (Table 2). A significant positive 
correlation was found between the following parameters: CRP 
and SVG disease (luminal diameter reduction; %/month; p<0.01), 
Hcy and SVG disease (p<0.01), CRP and Hcy (p<0.01), as well as 
vitamin B12 and folic acid (p<0.01); while a significant (p<0.05) but 
negative correlation was seen between triglycerides and HDL-
cholesterol. As patients with renal failure were not included, 
elevated creatinine values (>160 mmol/L) could be excluded as 
confounders of increased Hcy levels. 
By stepwise forward multivariate linear regression analysis 
(Table 3, Fig. 1), only Hcy was associated independently and sig-
nificantly with SVG disease; a 1 μmol/L increase in Hcy level was 
associated with a 0.053% increase in lumen diameter reduction/
month (R2=0.428; p<0.01), based on the corresponding patient 
coronary angiograms. Theoretically, this means that +10 μmol/L 
increase of Hcy level could be responsible for +32.1% luminal re-
duction in SVG within 5 years. A representative case of a CABG 
patient with venous graft degeneration is shown in Figure 2 (a-c).
Discussion
In this study, the patency rate was observed throughout the 
5.6-year follow-up to be 74.4%, which was similar to previously 
published results but higher than that reported by Sabik (15) (65%) 
and less than that recorded by Hayward (16) (86%) and Collins 
(17) (86.4%). Harris (18) has found an association between plas-
ma Hcy and LDL levels in 77 CAD patients 2 years after CABG. 
Our results could not confirm this, although we highlight the po-
tential role of certain factors in medium-term SVG degeneration 
in contrast with short-term graft occlusions. Our results for lipid 
parameters were in line with previous clinical observations that 
a remarkable proportion of high-risk CAD patients do not achieve 
their therapeutic goals (19). Despite the fact that our patient pop-
ulation received standard statin therapy, the total-cholesterol 
levels did not differ significantly between patient groups. Statin 
treatment may slow down the atherosclerotic process in SVGs 
independently from the achieved total-cholesterol level, which 
can be explained by the pleiotropic effect of statins (20).
Table 3. Predictors of SVG progression (dependent variable) in 
narrowed graft group (n=37)
Variable Coefficient P
Age 0.036 0.813
LDL 0.250 0.073
HDL 0.066 0.686
Tg 0.027 0.851
Chol 0.206 0.138
Creatinine 0.158 0.276
EF -0.157 0.272
CRP 0.098 0.537
HCy 0.053 p<0.01
Vit B12 0.075 0.632
R2=0.428; Adjusted R2=0.409
Method: multiple regression analysis; R2=0.428; Adjusted R2=0.409; Progression=SVG 
diameter lumen reduction (%) at follow-up per elapsed time (months). SVG was 
classified as narrowed showing 20–99% lumen diameter reduction at follow-up; Chol 
- cholesterin; CRP - c-reactive protein; EF - ejection fraction; Hcy - homocysteine; 
HDL - high-density lipoprotein; LDL - low-density lipoprotein; SVG - saphenous venous 
graft; Tg - triglyceride; vit B12 - vitamin B12
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Observed
It is to be noted that the lack of general folic acid/vitamin B 
supplementation in grain products for cardiovascular prevention 
in Hungary can be a potential cause of the relatively elevated 
plasma Hcy and low folic acid and vitamin B12 levels in the study 
population. Results of the univariate correlation analysis sug-
gested a correlation between CRP and the time proportional 
extent of SVG disease (r=0.483; p<0.01) as well as between CRP 
and Hcy (r=0.509; p<0.01) in SVG disease. The CRP–Hcy connec-
tion has been recently investigated in an animal model by Pang 
et al. (21). They found that Hcy can initiate an inflammatory re-
sponse by stimulating CRP production. In line with our findings, 
human and experimental data were published about the role of 
CRP in the in the pathogenesis of SVG disease (22, 23). However, 
other results of Auer (24) or Friso and colleagues (25) in CAD 
patients did not find association between the elevated hs-CRP 
level and total plasma Hcy.
Our conclusion was similar to Shammas’s (26) observations 
in 77 patients after 2 years that plasma Hcy is an independent 
prognostic factor of medium-term post-CABG graft degenera-
tion. Among the known risk factors of CAD, clinical and experi-
mental studies have confirmed a positive impact of Hcy on CAD 
(6, 27), but only few on SVG degeneration (26). Contrary to Rodi-
onov’s (28) observation that Hcy is only a bystander in CAD, our 
results support the opinion that Hcy plays an active role in SVG 
progression. Girelli et al. (29) observed similar results in 350 CAD 
patients after a mean follow-up of 4.8 years; Hcy was an impor-
tant and independent prognostic factor of mortality after CABG. 
Furthermore, fasting Hcy level correlated positively with CRP. It 
was previously published by researchers, e.g., by Chong et al (3) 
that shear stress in vessels induces compensatory mechanisms 
in endothelial cells, thus causing local vasodilatory release of 
nitric oxide and prostaglandins and inhibition of constricting fac-
tors (e.g., endothelin). This can beneficially affect neutrophil ad-
hesion and smooth muscle cell proliferation.
Study limitations
Limitations of the study include its retrospective and observa-
tional nature. Ideally, the question of how systemic and local risk 
factors (e.g., Hcy) affect medium- and long-term SVG progres-
sion should be addressed optimally in prospective randomized 
trials. The number of patients enrolled in this study was relatively 
low. We acknowledge that lack of baseline SVG angiography is a 
major limitation of this study. Status was recorded by coronary 
angiography, but the reasonable assumption was made that the 
grafts were intact at the time of CABG. Repeat coronary angio-
grams were indicated by clinical symptoms; therefore, the fre-
quency of SVG disease might have been overestimated as com-
pared to prospective angiography studies.
Where a single patient had ≥2 SVG conduits with different 
lumen status at follow-up, they were ranked according to the 
more severe graft’s status for classification into the group with 
intact or narrowed or occluded SVG grafts. Our per patient ap-
proach required the averaging of the stenosis of the grafts in the 
narrowed group. Exclusion of follow-up coronary angiographies 
within 12 months post-CABG reduced the study population but 
allowed the differentiation between short-term and chronic SVG 
disease development. The possibility of residual confounding 
factors in manifestation is presumable.
Conclusion
This study revealed further details regarding factors of graft 
disease in CABG patients. The long-term SVG degeneration 
shows correlation with the elevated plasma total Hcy in patients 
with sub-occlusive graft stenosis, while in cases with intact 
SVGs, the beneficial local flow conditions may protect the grafts 
from degeneration. Thereby intensity of elements can change by 
individuals making assessment of their real involvement difficult. 
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Elevated plasma total Hcy level should deserve attention in SVG 
patients regarding medium-term progression as Hcy seems to be 
associated with chronic SVG stenosis. Our data can be a promot-
er for further research to optimize prevention. We conclude that 
wide-scope risk management is an important objective of CABG 
patients for long-term success of their surgical treatment in CAD.
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